LVR-Klinikum Düsseldorf Hospital of the Heinrich-Heine University ...

eceived only brief information about the prevention of weight
gain. The remaining individuals (n=26) prematurely terminated
their participation during the screening phase or did not
fulfil inclusion criteria. In the diet group, a group therapy
was offered every fortnight over for weeks in which patients
worked interactively on eating and exercise behaviour with a
dietary assistant. The following parameters were assessed:
body mass index (BMI), physiological and laboratory
parameters (including glucose tolerance), eating behaviour
(FEV), physical activity (Freiburger Aktivitätsbogen), quality of
life (LQLP), health state (SF-36, CGI, PANSS) and psychosocial
adaptation (GAF). Follow-up was performed after 48 weeks.
Thirty-four percent of the participants completed the study.
At 48 weeks weight increase (PG: 5.2+7.9 kg, CG: 10.4+7.4
kg) and increase of waist circumference (PG: 4.6+8.3 cm,
CG: 10.7+7.3 cm) were lower in the prevention group (PG)
than in the control group (CG). However, the differences were
not significant. While the participants in the CG showed a
worsening of glucose metabolism in the glucose tolerance
test, this effect was prevented in the PG. These first results
indicate the preventive efficacy of weight management in
antipsychotic drug treatment of persons with schizophrenia
with respect to the development of impaired glucose
tolerance.
Double-blind comparison of the cardiovascular side
effects of olanzapine and clozapine in a randomised,
multi-centre study
R. Dittmann, A. Klimke, J. Cordes, C. Schmidt-Kraepelin,
F. Hellen, A. Ruttmann
Project period: 2004–2010
Financing: Lilly GmbH Deutschland
In this randomised, double-blind study, two groups of
patients were investigated. Of these, one received olanzapine
at daily doses of between 5 and 25 mg (women n=23, men
n=35), and the other clozapine at daily doses between 25 and
450 mg (women n= 22, men n=35). The study participants,
who were initially treated as inpatients, were weighed
before the start of treatment, during various visits and at
the end of the investigation after 26 weeks. An analysis of
variance was carried out with repeated measurements for
the factors medications and sex. In addition, Spearman’s
Rank Correlation Coefficient was calculated between
weight gain and age, initial weight and the ratios of
psychopathological scales (CGI-S, PANSS positive, negative
and general psychopathology scale). Results: both treatment
groups gained weight. There was no significant difference
between the mean weight gain (mean value ± SD) in study
ReseaRch
participants receiving olanzapine (+3.2± 5.7 kg) and those
receiving clozapine (+5.4±6.6 kg). In those treated with
olanzapine, there was no significant difference between
male and female study participants (p=0.986). Interestingly,
in those treated with clozapine, there was a significantly
larger weight gain in men than in women (p=.001). Overall,
younger individuals (r=-.237, p=.008) and individuals with
better treatment successes demonstrated greater weight
gains (CGI-S: r=-.385, p=.043; PANSS positive: r=-.281,
p=.003, PANSS negative: r=-.195, p=0.043; PANSS complete:
r=-.313, p=.001; SWN: r=.270, p=.005).
Effectiveness of weight management programmes for the
prevention of weight gain in patients with schizophrenia
treated with olanzapine: a randomised, multi-centre,
controlled open study
J. Cordes, G. Juckel, M. Bruene, C. Schuhmacher, J. Hahn,
U. Sprick, A. Horn, H. Eich, J. Hummes
Project period: from 2009
Financing: Lilly GmbH Deutschland
This study evaluates the BELA psychoeducative manual,
which is already used extensively in clinical practice, with
regard to the effect of preventing weight gain and metabolic
parameters in patients treated with olanzapine and
quetiapine.
105